Prothena Corporation plc (PRTA)

Market Cap	818.97M
Revenue (ttm)	133.35M
Net Income (ttm)	-131.83M
Shares Out	53.81M
EPS (ttm)	-2.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,495,872
Open	15.89
Previous Close	16.01
Day's Range	15.10 - 16.42
52-Week Range	11.70 - 41.55
Beta	0.06
Analysts	Buy
Price Target	46.50 (+205.52%)
Earnings Date	Feb 13, 2025

About PRTA

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 173
• Stock Exchange: NASDAQ
• Ticker Symbol: PRTA
• Website: https://www.prothena.com

Financial Performance

In 2023, Prothena Corporation's revenue was $91.37 million, an increase of 69.50% compared to the previous year's $53.91 million. Losses were -$147.03 million, 25.7% more than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for PRTA stock is "Buy." The 12-month stock price forecast is $46.5, which is an increase of 205.52% from the latest price.

Price Target

$46.5

(205.52% upside)

Analyst Consensus: Buy